Skip to main content
. 2021 Jun 29;10(7):1626. doi: 10.3390/cells10071626

Figure 1.

Figure 1

Lipid-lowering drugs (LLDs) do not affect Hepatitis C virus (HCV) genotype 1a entry into Huh-7.5 cells. Effect of LLD on HCV entry and cell viability. Dose-response of lentiviral pseudoparticle (pp) entry into Huh-7.5 (A,C,E). Cells were preincubated for 24 h with increasing concentrations of either simvastatin (A), fenofibrate (C), or alirocumab (E) before transduction with NLuc-encoding pps bearing E1-E2 GT1a glycoprotein (GP) (HCV), MLV env (MLV) for 6 h. NLuc activity was measured 72 h post-transduction (hpt) and luciferase activity was normalized to solvent control. MLVpp entry served as virus control. Drug-induced cytotoxicity (B,D,F). Huh-7.5 cells constitutively expressing NLuc (Huh-7.5/NLuc) were treated with either simvastatin (B), fenofibrate (D) or alirocumab (F) for 30 h as for (B,D,F) but were not transduced. Ninety-six h after treatment, NLuc activity was measured and luciferase activity values were normalized to DMSO control. When determined, CC50 values were indicated at the lower left side of the graph. Graphs represent the average of three independent experiments performed in triplicate with error bars representing the standard deviation (SD).